Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737301

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737301

Oncolytic Virus Immunotherapy

PUBLISHED:
PAGES: 383 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Oncolytic Virus Immunotherapy Market to Reach US$429.1 Million by 2030

The global market for Oncolytic Virus Immunotherapy estimated at US$156.8 Million in the year 2024, is expected to reach US$429.1 Million by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Herpes Simplex Virus, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$189.7 Million by the end of the analysis period. Growth in the Vaccinia Virus segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.7 Million While China is Forecast to Grow at 24.8% CAGR

The Oncolytic Virus Immunotherapy market in the U.S. is estimated at US$42.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$99.7 Million by the year 2030 trailing a CAGR of 24.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.5% and 16.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

Global Oncolytic Virus Immunotherapy Market - Key Trends & Drivers Summarized

Why Are Oncolytic Viruses Re-emerging as a Disruptive Modality in Cancer Immunotherapy?

Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming. These genetically engineered or naturally occurring viruses selectively infect and replicate in tumor cells, causing their destruction while releasing tumor-associated antigens that stimulate anti-cancer immune responses. Unlike traditional chemotherapy or radiation, oncolytic viruses act locally at the tumor site and systemically through immune activation, positioning them as versatile agents in both solid and hematologic malignancies.

Despite early setbacks in the 1990s, recent advances in molecular virology, gene editing, and immune-oncology have revitalized interest in this approach. The 2015 approval of T-VEC (talimogene laherparepvec) by the FDA for melanoma marked a watershed moment, validating the concept of oncolytic virus therapy in clinical practice. Since then, a surge of clinical trials targeting multiple cancer types-including glioblastoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer-has expanded the scope and credibility of the modality. As monotherapies and in combination with checkpoint inhibitors, oncolytic viruses are becoming a cornerstone of next-generation immunotherapy regimens.

How Are Genetic Engineering and Combination Protocols Expanding the Potential of Oncolytic Virotherapy?

Recent breakthroughs in synthetic biology and vector engineering are significantly enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses. New viral constructs-based on herpes simplex virus (HSV), adenovirus, vaccinia virus, and reovirus-are being armed with immune-boosting transgenes such as GM-CSF, interleukins, or checkpoint blockade peptides. These modifications allow the virus to not only destroy tumor cells but also convert the tumor microenvironment (TME) into an immunologically active site.

Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.

Which Tumor Types and Geographies Are Shaping the Clinical and Commercial Landscape for Oncolytic Viruses?

Solid tumors with immunosuppressive microenvironments-such as melanoma, glioblastoma, pancreatic cancer, and hepatocellular carcinoma-are prime candidates for oncolytic virotherapy. These cancers typically respond poorly to conventional therapies and often lack T-cell infiltration, which oncolytic viruses can help overcome. Hematologic malignancies like lymphoma and multiple myeloma are also being targeted through engineered viruses capable of engaging both innate and adaptive immunity.

North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.

What Is Powering Long-Term Growth and Scientific Innovation in the Oncolytic Virus Immunotherapy Market?

The growth in the oncolytic virus immunotherapy market is powered by a paradigm shift toward immune-driven cancer control, rising incidence of refractory tumors, and growing regulatory openness to gene-modified biologicals. Oncolytic viruses offer a platform approach with customizable payloads and delivery options, making them highly adaptable to evolving immuno-oncology landscapes. Their ability to initiate cold-to-hot tumor conversion addresses one of the biggest challenges in cancer immunotherapy today.

Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virus Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types); Administration Route (Intratumoral Route, Intravenous Route); Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Amgen Inc.
  • CG Oncology
  • Creative Biolabs
  • Daiichi Sankyo Co., Ltd.
  • Genelux Corporation
  • ImmVirX
  • Imugene Limited
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Oncolys BioPharma Inc.
  • Oncolytics Biotech Inc.
  • Oncorus Inc.
  • Replimune Group Inc.
  • SillaJen, Inc.
  • Sorrento Therapeutics, Inc.
  • Syneos Health, Inc.
  • TILT Biotherapeutics Ltd.
  • Transgene S.A.
  • Viralytics Ltd.
  • ViraTherapeutics GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34136

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Oncolytic Virus Immunotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Precision Oncology Spurs Development of Oncolytic Virus Platforms With Tumor Selectivity
    • Expansion of Immunotherapy Research Pipelines Strengthens Business Case for Oncolytic Virus Modalities
    • Increased Approval of Cancer Immunotherapies Throws the Spotlight on Next-Generation Viral Vectors
    • Breakthrough Designation Status and Fast Track Approvals Accelerate Regulatory Momentum
    • Advancements in Genetic Engineering of Viruses Drive Enhanced Tumor Targeting and Immune Activation
    • Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons
    • Increased Use of Oncolytic Viruses as Neoadjuvant Therapies Supports Multimodal Cancer Management
    • Growing Investment From Biopharma and Venture Capital Enhances Innovation and Clinical Translation
    • Development of Tumor-Specific Viral Payloads Strengthens Oncolytic Virus Selectivity and Safety Profiles
    • Adoption of Intratumoral and Systemic Delivery Routes Expands Accessibility to Diverse Tumor Types
    • Improved Understanding of Tumor Microenvironment Enhances Viral Mechanism Optimization
    • Collaborative Efforts Between Academia and Industry Propel Translational Research in Viral Oncology
    • Expansion of Cold Chain Logistics Infrastructure Supports Global Supply of Virus-Based Therapies
    • Public and Philanthropic Funding for Rare Cancer Treatment Drives Orphan Application Development
    • Manufacturing Scale-Up of Viral Vectors Remains a Bottleneck for Commercialization Readiness
    • Development of Immune Response Biomarkers Facilitates Patient Selection and Treatment Monitoring
    • Increased Advocacy for Personalized Cancer Immunotherapy Supports Patient Enrollment in Viral Trials
    • Challenges in Viral Shedding and Immunogenicity Highlight Need for Improved Safety Profiling
    • Rising Global Cancer Incidence and Limited Success in Refractory Cancers Propel Need for Disruptive Modalities
    • Regulatory Alignment on Gene and Virus Therapies Enhances Global Clinical Trial Harmonization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oncolytic Virus Immunotherapy Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Vaccinia Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Reovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pancreatic Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pancreatic Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pancreatic Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Non-small Cell Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Non-small Cell Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Non-small Cell Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Intratumoral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Intratumoral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Intratumoral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Intravenous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • JAPAN
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • CHINA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • EUROPE
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • FRANCE
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • GERMANY
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • INDIA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • AFRICA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!